Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy
about
Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trialPost-HAART outcomes in pediatric populations: comparison of resource-limited and developed countriesPerformance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patientsInterpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphismAdherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management.Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.Impact of pharmacogenetics on CNS side effects related to efavirenz.Randomized exposure-controlled trials; impact of randomization and analysis strategies.Population pharmacokinetics of tenofovir in AIDS patients.
P2860
Q33765130-350CF045-ADC1-49F3-8A21-68A4815DDB13Q34513045-5298653C-EAF6-4694-9C2D-D7ECDFC3EE5BQ34879068-6BEA2117-8D32-4A68-A5A6-9B3B8BF45882Q35364120-2480A6F5-D1AD-431E-9327-24BA7A643A2BQ35826686-6AD170DB-6A73-42AE-B4DC-C47BDC1845C0Q35827416-064AEF74-AFF6-41F5-B5B8-82CCF86B4103Q36833521-B32B1DD7-30C0-4B51-86E4-A828DA10A391Q36877237-86F4E19E-85A6-45D5-BD11-2558860ABE3DQ37237006-6BFE5AEE-EEF7-4D99-998F-B464583AD820Q37471061-6A1B2EDE-B403-41A8-9294-65F7248F1A79Q37519804-ECF6A4B4-30D9-4AAA-A4DF-001CC5212B0EQ37544540-E1EA0697-15E5-449E-823C-E8EB892062B0Q37600844-8A4A7C67-9EC5-440C-81AF-F92124F7D196Q37835819-10987E28-E6A0-4C4C-8566-AD51F60FE9D9Q38377051-1A70002E-AD2C-429F-8667-22CBBF623898Q38868951-DA3D8832-FA13-4579-97C5-9778F2E3A863Q38890298-0402D174-C267-4E85-8E66-5091702782C8Q39383647-7E72D144-B690-4B1F-84E6-B1FD1D3C877EQ41121488-30E00CFF-E390-4A50-90DC-7F54E67A30C5Q45349377-DF2CB85B-70C0-42A9-9B95-C12F5E19106B
P2860
Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Intrapatient variability of ef ...... onse to antiretroviral therapy
@ast
Intrapatient variability of ef ...... onse to antiretroviral therapy
@en
type
label
Intrapatient variability of ef ...... onse to antiretroviral therapy
@ast
Intrapatient variability of ef ...... onse to antiretroviral therapy
@en
prefLabel
Intrapatient variability of ef ...... onse to antiretroviral therapy
@ast
Intrapatient variability of ef ...... onse to antiretroviral therapy
@en
P2093
P2860
P1476
Intrapatient variability of ef ...... onse to antiretroviral therapy
@en
P2093
Courtney V Fletcher
Florence H Yong
Richard C Brundage
Stephen A Spector
Terence Fenton
P2860
P304
P356
10.1128/AAC.48.3.979-984.2004
P407
P577
2004-03-01T00:00:00Z